Antag starts Phase 2a trial testing new weight loss and diabetes combo drug
Antag has dosed the first patient in a Phase 2a trial evaluating AT7687 in combination with semaglutide for people with overweight or obesity and type 2 diabetes, according to the company. The multi-center, randomized, double-blind 13-week study will enroll 150 participants in the United States, ran
<p>Antag has dosed the first patient in a Phase 2a trial evaluating AT7687 in combination with semaglutide for people with overweight or obesity and type 2 diabetes, according to the company. The multi-center, randomized, double-blind 13-week study will enroll 150 participants in the United States, ran</p>